Skip to main content
letter
. 2020 Feb;8(4):141. doi: 10.21037/atm.2019.11.52

Figure 1.

Figure 1

Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes. (A) Prevalence of KEAP1 mutations in different cancer types; (B) the association between TMB and KEAP1 mutations in MSK-IMPACT cohort; (C) the association between TMB and KEAP1 alterations in immune checkpoint inhibitors treatment cohort; (D) prognostic value of KEAP1 mutations in all cancers; (E) prognostic value of KEAP1 mutations in early-stage cancers (TCGA cohort); (F) prognostic value of KEAP1 mutations in advanced-stage cancers (MSK-IMPACT cohort); (G) predictive value of KEAP1 mutations in patients received ICI therapy; (H) the association between KEAP1 mutations and six immune infiltrates in lung adenocarcinoma; (I) the association between KEAP1 mutations and six immune infiltrates in lung squamous cell carcinoma. LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; Mut, mutation; WT, wild type; TMB, tumor mutation burden; ICI, immune checkpoint inhibitor.